OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
Ying Cheng, Qing Zhou, Baohui Han, et al.
Lung Cancer (2023) Vol. 178, pp. 87-95
Open Access | Times Cited: 6
Ying Cheng, Qing Zhou, Baohui Han, et al.
Lung Cancer (2023) Vol. 178, pp. 87-95
Open Access | Times Cited: 6
Showing 6 citing articles:
Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer
Prabhjot Kaur, Santosh Kumar Singh, Manoj K. Mishra, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2205-2205
Open Access | Times Cited: 5
Prabhjot Kaur, Santosh Kumar Singh, Manoj K. Mishra, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2205-2205
Open Access | Times Cited: 5
Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis
Xianjing Chu, Wentao Tian, Jiaoyang Ning, et al.
JNCI Journal of the National Cancer Institute (2024) Vol. 116, Iss. 10, pp. 1571-1586
Closed Access | Times Cited: 5
Xianjing Chu, Wentao Tian, Jiaoyang Ning, et al.
JNCI Journal of the National Cancer Institute (2024) Vol. 116, Iss. 10, pp. 1571-1586
Closed Access | Times Cited: 5
Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
Huimin Zhao, Shanshan Huang, Jianyu Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Huimin Zhao, Shanshan Huang, Jianyu Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Ziling Huang, Shen Wang, Jiansong Zhou, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 7
Open Access
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Ritu Yadav, Rinku Khatkar, Kenneth C-H Yap, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Ritu Yadav, Rinku Khatkar, Kenneth C-H Yap, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibitors for Advanced or Metastatic Non–Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Wei Ren, Yingying Fang, Yu‐Jing He, et al.
Therapeutic Drug Monitoring (2024)
Open Access
Wei Ren, Yingying Fang, Yu‐Jing He, et al.
Therapeutic Drug Monitoring (2024)
Open Access
